← FDA DRUG APPROVALS

FDA ANDA · ANDA206691

PERPHENAZINE

Sponsor: MYLAN

APPLICATION
ANDA206691
TYPE
ANDA
ORIGINAL APPROVAL
2017-04-14
LATEST ACTION
2025-01-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

PERPHENAZINEDiscontinued
PERPHENAZINE 16MG · TABLET · ORAL
PERPHENAZINEDiscontinued
PERPHENAZINE 4MG · TABLET · ORAL
PERPHENAZINEDiscontinued
PERPHENAZINE 8MG · TABLET · ORAL
PERPHENAZINEDiscontinued
PERPHENAZINE 2MG · TABLET · ORAL

Approval history

2025-01-22Labeling · Supplement 2 · standardAP
2017-04-14UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →